Cross-Neutralizing Activity of Monoclonal Antibodies Against N501Y Mutant Strain of SARS-CoV-2 | Zendy

Ruxia Ding | Zendy; Haixin Wang | Zendy; Yi Yang | Zendy; Liangshu Xie | Zendy; Li Zhang | Zendy; Qianqian Li | Zendy; Shuo Liu | Zendy; Jianhui Nie | Zendy; Jiajing Wu | Zendy; Haiyang Qin | Zendy; Yuelei Shen | Zendy; Huiguo Wang | Zendy; Weijin Huang | Zendy; Y Wang | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Cross-Neutralizing Activity of Monoclonal Antibodies Against N501Y Mutant Strain of SARS-CoV-2

Author(s) -

Ruxia Ding,

Haixin Wang,

Yi Yang,

Liangshu Xie,

Li Zhang,

Qianqian Li,

Shuo Liu,

Jianhui Nie,

Jiajing Wu,

Haiyang Qin,

Yuelei Shen,

Huiguo Wang,

Weijin Huang,

Y Wang

Publication year - 2020

Publication title -

journal of applied virology

Language(s) - English

Resource type - Journals

eISSN - 2306-6210

pISSN - 2305-5154

DOI - 10.21092/jav.v9i4.90

Subject(s) - neutralization , mutant , monoclonal antibody , virology , covid-19 , infectivity , strain (injury) , neutralizing antibody , antibody , mutation , spike protein , biology , virus , gene , genetics , medicine , disease , pathology , anatomy , infectious disease (medical specialty) , outbreak

The dominant N501Y mutation in the spike protein that SARS-CoV-2 virus uses to bind to the human ACE2 receptor were found in the UK, which has aroused global concern and worried. Mutations in spike protein may, in theory, result in more infectious and spreading more easily. In order to evaluate the broad-spectrum protective effect of the monoclonal antibodies(mAbs), we compared the neutralization activities of six prepared mAbs against SARS-CoV-2 with pseudovirus neutralization assay. Only one of them showed a decrease of 6 folds in neutralizing activity to N501Y mutant strain, compared with the wild type strain. We should continue to monitor emergence of new variants in different regions to study their infectivity and neutralization effect.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research